Globally, the infrequent rate of BRAF V600E mutation observed in MM limits the efficacy of BRAF inhibitors, largely used in cutaneous melanoma, while the higher NRAS and c-KIT mutations rates make them potentially susceptible to NRAS and c-Kit target therapies [5, 22, 61, 75]. The gene discussed is BRAF; the disease is cutaneous melanoma.